In recent years, the China’s biopharmaceutical industry has developed rapidly, accounting for a larger and larger proportion in the world’s biopharmaceutical market. However, China's biopharmaceutical industry started later than developed countries, which is far behind developed countries. The international market share of American, European and Japanese enterprises has reached 59%, 19% and 17% respectively, while that of China and other countries is less than 5%. Therefore, China must improve the international competitiveness of the biopharmaceutical industry. In this paper, using the theory of international competitiveness as the foundation, from the drug quality, professional talents, knowledge, skills, money, and related infrastructure, government policy, etc., studies the influence factors of affect the biological medicine industry in China and puts forward some corresponding suggestions and countermeasures, in order to improve the production’s international competitive advantage in China.

Lin Zhu. The Appraisal and Countermeasure Analysis of the Export Competitiveness of biopharmaceutical Industry in China. International Journal of Frontiers in Sociology (2021), Vol. 3, Issue 17: 50-52. https://doi.org/10.25236/IJFS.2021.031707.

[1] IMS, health. Development status and future trend of biopharmaceuticals in the world and China [J]. Science and Technology China, 2016(4):54-59.

[2] QIANZHAN. Report of Market Prospective and Investment Strategy Planning on China Medicines Industry(2021-2026) [EB/OL], 2021

[3] Guo Xiaodan. China's import and export of biomedical products grew strongly. Fine and Specialty Chemicals 23.12 (2015): 9-13

[4] Zhang Beibei. Analysis of China's pharmaceutical foreign trade friction situation in 2017 [J]. Fine and special chemicals, 2018,26 (03): 1-3

[5] Zhang K, Liu W. The current status, trend and development strategies of the biopharmaceutical industry with a challengingperspective of Chinese industry. 2019.